Monte Rosa Therapeutics Revenue and Competitors

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Monte Rosa Therapeutics's estimated annual revenue is currently $9.5M per year.(i)
  • Monte Rosa Therapeutics's estimated revenue per employee is $63,456
  • Monte Rosa Therapeutics's total funding is $223.5M.

Employee Data

  • Monte Rosa Therapeutics has 149 Employees.(i)
  • Monte Rosa Therapeutics grew their employee count by 24% last year.

Monte Rosa Therapeutics's People

CEOReveal Email/Phone
VP, Discovery SciencesReveal Email/Phone
SVP, Chemical Sciences and Process DevelopmentReveal Email/Phone
Head CADD and Computational ChemistryReveal Email/Phone
VP, OperationsReveal Email/Phone
VP, Head ChemistryReveal Email/Phone
VP Intellectual PropertyReveal Email/Phone
SVP and General CounselReveal Email/Phone
VP Nonclinical Development & Clinical PharmacologyReveal Email/Phone
SVP, Head Business DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is Monte Rosa Therapeutics?

Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020. Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Monte Rosa Therapeutics News

2022-04-06 - Monte Rosa Therapeutics Presents Preclinical Data ...

Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven...

2022-03-22 - Monte Rosa Therapeutics Reports Fourth Quarter and Full ...

BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular...

2021-06-25 - Monte Rosa Therapeutics raises USD222 million in successful IPO

After VectivBio, Gain Therapeutics, Pharvaris and NLS Pharmaceutics, Monte Rosa Therapeutics is already the fifth biotech company with Swiss roots going public on Nasdaq in 2021. Monte Rosa Therapeutics is developing a portfolio of novel small molecule precision medicines that employ the body’s ...

2021-03-19 - Monte Rosa closes $95 million series C round

Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine based in Basel and is active in both Boston and Basel. With the core focus on discovering and developing molecular glues to degrade disease-causing proteins, the company has created a platform to rational ...

2021-03-16 - Monte Rosa Therapeutics Raises $95M in Series C Financing

Monte Rosa Therapeutics, a Boston, MA-based biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, closed a $95m Series C financing. The round was led by Avoro Capital Advisors with participation from additional new investors Fidel ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding